Loading...
(Video from the Internet)
The National Health Insurance Administration exposed 25 untrustworthy pharmaceutical companies
A few days ago, the National Health Insurance Administration's Pharmaceutical Price and Bidding and Procurement Guidance Center released the situation of pharmaceutical companies rated as "particularly serious" and "serious" as of March 31, 2024 in various provinces, of which 4 pharmaceutical companies were rated as "particularly serious" and 21 pharmaceutical companies were rated as "serious".
Picture: List of 25 dishonest enterprises. (Official website of the National Health Insurance Administration)
According to reports, the credit rating of price procurement is mainly determined based on the severity of the amount of bribes, unfair price behavior, and disruption of the order of centralized procurement. For example, a single bribe of more than 10,000 yuan is considered "average", a single bribe of more than 100,000 yuan is considered "moderate", a single bribe of more than 300,000 yuan is considered "serious", and a single bribe of more than 2 million yuan is "particularly serious".
Based on the credit rating of the pharmaceutical enterprise, the relevant departments may take measures such as reminding and admonishing, reminding of risks, and disclosing information on untrustworthiness, up to restricting or suspending the enterprise's involvement in the case or all drugs and medical consumables on the Internet, bidding or distribution qualifications. For example, for enterprises rated as "serious", measures such as canceling the qualifications for online listing and distribution of the products involved in the case are to be employed, and for enterprises rated as "particularly serious", measures such as canceling the qualifications for online listing and distribution of all products are to be adopted.
Source: Xinhua News Agency, Dazhong Daily, Xinjiang Radio and Television Station